Summary of Cullinan Therapeutics Conference Call Company Overview - **Company**: Cullinan Therapeutics (NasdaqGS: CGEM) - **Year**: 2026 is highlighted as a potentially defining year for the company with multiple milestones across programs, particularly focusing on T-cell engager programs CLN-978 and CLN-049 [17][21] Key Programs and Developments CLN-978 (CD19xCD3 T-cell engager) - **Indications**: Targeting autoimmune diseases such as lupus, rheumatoid arthritis (RA), and Sjögren's disease - **Differentiation**: Claimed to be a potential best-in-class molecule with high affinity binding for CD19 and small molecular size for better tissue penetration [17][18] - **Clinical Data Timeline**: - Q2 2026: Initial clinical data from systemic lupus erythematosus (SLE) and RA - Q3 2026: Initial multi-dose data from RA - Q4 2026: Initial data from Sjögren's disease study [18] - **Market Interest**: The B-cell depletion space remains attractive, as evidenced by recent acquisitions in the sector [18] CLN-049 (FLT3xCD3 T-cell engager) - **Indication**: Focused on acute myeloid leukemia (AML) - **Efficacy Data**: Presented compelling monotherapy efficacy data at ASH, with Fast Track designation from the FDA received [19] - **Clinical Development**: - Plans to initiate a phase 1/2 study in combination with venetoclax in the frontline setting by the end of 2026 [19][94] - Aiming for a pivotal study in relapsed refractory disease [19] Zipalertinib - **Milestone**: Completed NDA submission, marking a significant achievement for the company [20] Financial Position - **Cash Reserves**: Over $430 million reported at the end of the previous year, providing a runway into 2029 to advance programs [21] Competitive Landscape - **Positioning**: CLN-978 is positioned against other CD19 T-cell engagers, with a focus on its high binding affinity and small size for better tissue penetration [42][43] - **Competitors**: Companies like Roche, Novartis, Merck, and GSK are mentioned as competitors, with some being further behind in development [42][43] Clinical Insights and Data - **B-cell Depletion**: Emphasized the importance of deep B-cell depletion for achieving treatment-free remission in autoimmune diseases [26][27] - **Durability of Response**: Noted that some patients have achieved treatment-free responses lasting several years, particularly in diseases like systemic lupus erythematosus [33] - **Safety Profile**: Initial studies showed favorable safety profiles with low rates of cytokine release syndrome (CRS) [67][92] Future Outlook - **Upcoming Data**: Anticipated updates at ASH or EHA, with a focus on further dose escalation and durability of response [95][96] - **Regulatory Pathway**: Clear development pathway for AML with potential for approval in relapsed refractory disease through a single-arm study [94] Conclusion - **Strategic Focus**: Cullinan Therapeutics is poised for a significant year in 2026 with multiple clinical milestones, a strong financial position, and a competitive edge in the T-cell engager space, particularly in autoimmune diseases and AML [21][94]

Financial Performance - The company reported total operating expenses of $241.6 million in 2025, an increase of 22.6% from $196.9 million in 2024[487]. - The net loss for 2025 was $219.9 million, compared to a net loss of $167.6 million in 2024, reflecting a 31.2% increase in losses year-over-year[487]. - The accumulated deficit as of December 31, 2025, was $588.1 million, indicating significant operating losses since inception[479]. - The net cash used in operating activities for 2025 was $175.8 million, compared to $145.3 million in 2024, indicating an increase in operational cash burn[499]. - The company reported a decrease in interest income to $22.2 million in 2025 from $29.7 million in 2024, a decline of 25.1%[487]. Cash and Investments - The company had cash, cash equivalents, and short-term investments totaling $377.9 million as of December 31, 2025[479]. - As of December 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $377.9 million, with long-term investments and interest receivable of $61.1 million[493]. - The company expects its current cash and investments to fund operations into 2029, although this is based on assumptions that may prove incorrect[494]. - The company completed a private placement in April 2024, raising net proceeds of $262.7 million after deducting offering costs of $17.3 million[496]. - The company has an at-the-market equity offering program allowing for the sale of up to $125.0 million of common stock, with $85.6 million remaining as of December 31, 2025[497]. Research and Development - Research and development expenses rose to $187.4 million in 2025, up from $142.9 million in 2024, primarily due to a one-time upfront in-licensing fee for velinotamig of $20 million[488]. - The ongoing Phase 1 OUTRACE Program for CLN-978 is expected to share initial clinical data in systemic lupus erythematosus and rheumatoid arthritis in Q2 2026 and Q3 2026, respectively[470]. - Zipalertinib is being evaluated in a pivotal Phase 2b trial, with a rolling submission for NDA seeking accelerated approval expected to be completed by February 2026[470]. - The company plans to begin enrolling dose expansion cohorts for CLN-049 in Q2 2026, with completion of enrollment expected by Q4 2026[470]. - Future funding requirements are expected to increase significantly due to ongoing research, development, and commercialization activities[505]. Licensing and Agreements - The company entered into a license agreement with Genrix in June 2025, paying an upfront fee of $20.0 million for the exclusive rights to develop and commercialize velinotamig[495]. - The company is eligible to receive up to $130.0 million in payments from Taiho upon U.S. regulatory approval of zipalertinib for specific cancer treatments[498]. Lease Obligations - Total future minimum lease payments as of December 31, 2025, were $3.1 million, with $1.0 million due within 12 months[509]. Regulatory and Compliance - The company is classified as a smaller reporting company and is not required to provide detailed market risk disclosures[520].

Core Insights - Cullinan Therapeutics is advancing multiple clinical programs with significant milestones expected throughout 2026, including initial data for CLN-978 in autoimmune diseases and updates on zipalertinib for oncology [1][2][3] Financial Overview - As of December 31, 2025, the company reported cash and investments totaling $439.0 million, providing a financial runway into 2029 [1][10] - Research and development expenses for Q4 2025 were $42.9 million, an increase from $40.5 million in Q4 2024, while total R&D expenses for the full year 2025 reached $187.4 million compared to $142.9 million in 2024 [5][11] - General and administrative expenses for Q4 2025 were $12.3 million, down from $14.6 million in Q4 2024, with full-year G&A expenses slightly increasing to $54.2 million from $54.0 million [5][11] - The net loss attributable to Cullinan was $50.7 million for Q4 2025, compared to $47.6 million in Q4 2024, and $219.9 million for the full year 2025, up from $167.4 million in 2024 [5][11] Clinical Development Highlights - CLN-978, a CD19xCD3 bispecific T cell engager, is set to provide initial data for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in Q2 2026, with repeat dosing data expected in Q3 2026 [4] - Zipalertinib's rolling NDA submission has been completed, and the REZILIENT3 frontline study has been fully enrolled, with top-line results anticipated by the end of 2026 [1][3] - CLN-049, targeting acute myeloid leukemia (AML), is expected to advance to registrational development following promising clinical data and is set to initiate monotherapy dose expansion cohorts in Q2 2026 [4][8] Strategic Partnerships and Collaborations - The company is collaborating with Taiho Oncology on zipalertinib, which is nearing regulatory approval for treating EGFR ex20ins non-small cell lung cancer (NSCLC) [3][8] - Genrix Bio is enrolling a Phase 1 study for velinotamig in autoimmune diseases, with initial clinical data expected in Q4 2026, which Cullinan plans to leverage for global development [4]

Summary of Cullinan Therapeutics Conference Call Company Overview - **Company**: Cullinan Therapeutics - **Key Personnel**: Nadim Ahmed (President and CEO), Jeff Jones (CMO) - **Event**: 46th Annual TD Cowen Healthcare Conference Key Milestones and Programs - **Transformational Year**: 2026 is anticipated to be a pivotal year for Cullinan Therapeutics with multiple catalysts and milestones across programs [2] - **Key Programs**: - **CLN-978**: A CD19 by CD3 T-cell engager targeting autoimmune diseases, with potential to be best in class. Development studies are ongoing in rheumatoid arthritis (RA), lupus, and Sjögren's disease, with initial data expected in Q2 2023 [2][3] - **CLN-049**: A FLT3 by CD3 bispecific T-cell engager for acute myeloid leukemia (AML), presenting a first-in-class immunotherapeutic approach. Promising monotherapy efficacy data was presented at ASH [4][34] Clinical Development Insights - **CLN-978**: - High affinity for CD19 and small molecular size may enhance tissue penetration and allow for subcutaneous administration [3] - Initial clinical data for RA and lupus expected in Q2 2023, with multi-dose data for RA in Q3 and Sjögren's disease data in Q4 [3][14] - The potential for treatment-free remissions is highlighted as a significant advantage over current therapies [6][24] - **CLN-049**: - Achieved a composite complete response (CR) rate of 31% at the highest dose tested (12 micrograms per kilogram), competitive with recent AML approvals [34] - The absence of biomarkers predicting response suggests a novel all-comer immunotherapy approach [35][38] Safety and Efficacy Considerations - **Safety Profile**: - Aim to minimize the rate of grade 2 cytokine release syndrome (CRS) to 10% or less, with grade 1 CRS being manageable [21][22] - Focus on preventing neurotoxicity, particularly immune effector cell-associated neurotoxicity syndrome (ICANS) [22] - **Efficacy Expectations**: - For CLN-978, achieving dose-dependent B-cell depletion and acceptable safety is critical for initial data [19][20] - For CLN-049, a response rate of 20% in patients with P53 mutations is considered clinically meaningful [41] Development Pathway - **Regulatory Strategy**: - Plans for accelerated development in specific subsets of autoimmune diseases if compelling efficacy and safety are demonstrated [28] - A systematic dose-finding regimen is being employed across multiple indications to streamline development [30] - **Future Updates**: - Data updates expected in Q2 2023, with ongoing dose escalation and expansion phases planned for later in the year [53][55] Market Context - **Industry Trends**: - The T-cell redirecting therapy space is gaining traction, with recent acquisitions indicating strong interest [4] - The standard of care in AML has remained stagnant, highlighting the need for innovative therapies like CLN-049 [33] Conclusion Cullinan Therapeutics is positioned for significant advancements in 2026, with promising data expected from its key programs CLN-978 and CLN-049. The focus on safety, efficacy, and a clear regulatory pathway will be crucial in navigating the competitive landscape of autoimmune diseases and AML therapies.

Company Overview - Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and immune-related diseases, founded in 2016 and based in Cambridge, Massachusetts [1] - The company is advancing a pipeline of promising candidates, including CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617 [1] Price Target Analysis - The consensus price target for CGEM stock has shown fluctuations, with the average price target increasing from $30 to $30.25 last quarter, but decreasing to $30.83 over the past year [2] - Morgan Stanley analysts have set a price target of $19 for CGEM, indicating a positive outlook for the company's stock [3][5] Investment Considerations - When considering investment in Cullinan Therapeutics, it is important to evaluate company news, clinical trial results, and broader market conditions [4] - The company's focus on oncology and immuno-oncology therapies, along with its promising pipeline, positions it well in the competitive biopharmaceutical industry [4][5]

Core Viewpoint - The article discusses the investment position in CGEM, highlighting a beneficial long position in the shares of the company through various means such as stock ownership and derivatives [1]. Group 1 - The analyst has a long position in CGEM shares, indicating confidence in the company's future performance [1]. - The article expresses personal opinions regarding CGEM without any external compensation, suggesting an independent analysis [1]. Group 2 - There is no specific financial data or performance metrics provided in the documents, focusing instead on the analyst's position and opinions [2][3].

Core Viewpoint - The session features Cullinan Therapeutics' leadership, highlighting the company's focus on oncology and its strategic direction in the biotech sector [1] Company Overview - Cullinan Therapeutics is represented by CEO Nadim Ahmed and CMO Jeff Jones during the Citi's Virtual Oncology Leadership Summit [1] Industry Context - The event is part of Citi's initiative to engage with key players in the oncology field, reflecting the growing importance of biotech in addressing cancer treatment [1]

Summary of Cullinan Therapeutics Conference Call Company Overview - **Company**: Cullinan Therapeutics (NasdaqGS: CGEM) - **Date**: February 19, 2026 - **Event**: Citi's Virtual Oncology Leadership Summit Key Points Oncology Pipeline Development - **2026 Significance**: Cullinan Therapeutics anticipates multiple catalysts across its oncology pipeline, particularly for T-cell engagers CLN-978 and CLN-049 [6][72] - **CLN-978**: A CD19 by CD3 T-cell engager targeting autoimmune diseases with a global development program aimed at lupus, rheumatoid arthritis (RA), and Sjögren's disease. The molecule is noted for its high binding affinity and potential to replace monoclonal antibodies [7][8] - **CLN-049**: A FLT3 x CD3 T-cell engager for acute myeloid leukemia (AML), presenting a first-in-class opportunity. The company aims to transition from dose escalation to dose expansion and is utilizing Fast Track designation from the FDA to select a recommended phase II dose [9][11] Clinical Data and Efficacy - **CLN-049 Efficacy**: Presented compelling monotherapy efficacy data at ASH 2025, with a complete response rate of approximately 30% and durable responses observed in patients, including those with P53 mutations [20][41] - **Safety Profile**: The safety profile of CLN-049 is favorable, with a lower incidence of cytokine release syndrome (CRS) compared to other T-cell engagers [21][22] Market Opportunity - **AML Market Size**: Approximately 20,000 new AML cases annually in the US, with a significant relapse/refractory patient pool. The potential market for CLN-049 in this segment is estimated to be a billion-dollar opportunity, with further expansion into frontline settings potentially unlocking multi-billion dollar opportunities [57][58] Financial Position - **Cash Reserves**: As of December 2025, Cullinan reported over $430 million in cash, providing a runway into 2029 to support ongoing programs [15] Zipalertinib Development - **Partnership with Taiho**: Zipalertinib, an EGFR exon 20 tyrosine kinase inhibitor, is in collaboration with Taiho, which is completing a rolling NDA submission. The agreement includes a 50/50 profit share in the US and $130 million in regulatory milestones [12][61] - **Market Potential**: The annual diagnosis of exon 20 non-small cell lung cancer in the US is estimated at 3,000-5,000 patients, presenting a significant market opportunity [60] Future Milestones - **Upcoming Data Releases**: Data updates for CLN-049 are expected in the second half of 2026, with dose expansion cohorts planned for initiation in Q2 2026 [70][71] - **Regulatory Pathway**: The company is confident in pursuing accelerated approval pathways for both CLN-049 and zipalertinib, with clear development strategies outlined [46][48] Conclusion - **2026 Outlook**: Cullinan Therapeutics is positioned for a transformative year with multiple catalysts across its oncology and autoimmune pipelines, aiming to create shareholder value through strategic advancements and regulatory approvals [72]

Group 1 - Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing potential first- or best-in-class therapies for autoimmune diseases and cancer [3] - The company will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on February 19, 2026, featuring CEO Nadim Ahmed and CMO Jeffrey Jones [1] - The fireside chat will be accessible via a webcast on the company's investor relations website [2] Group 2 - Cullinan Therapeutics leverages expertise in T cell engagers, which are established in oncology and are now being advanced into autoimmune diseases [3] - The company aims to deliver new standards of care for patients through a clinical-stage pipeline built on rigorous scientific approaches and purposeful innovation [3]

Summary of Cullinan Therapeutics 2026 Conference Call Company Overview - **Company**: Cullinan Therapeutics (NasdaqGS: CGEM) - **Focus**: Development of T cell engager programs for autoimmune diseases and oncology Key Priorities and Portfolio - **2026 Significance**: First year with catalysts across the entire portfolio, particularly for two high-priority T cell engager programs: - **CLN-978**: CD19 x CD3 bispecific T cell engager for autoimmune diseases - **CLN-049**: FLT3 x CD3 T cell engager for acute myeloid leukemia (AML) [5][6] CLN-978 Program - **Potential**: Considered a best-in-class molecule for autoimmune diseases with a global development program targeting lupus, rheumatoid arthritis (RA), and Sjögren's disease [6] - **Differentiation**: High binding affinity for CD19, small molecular size for better tissue penetration, and subcutaneous administration convenience [6] - **Data Readouts**: Planned throughout 2026 for all three indications [6] - **Market Interest**: B cell depletion remains a hot area, with strategic acquisitions in the sector, indicating strong market interest [7] CLN-049 Program - **Potential**: First-in-class potential for a broad group of AML patients, with compelling monotherapy efficacy data presented at ASH [8] - **Regulatory Designation**: Received Fast Track designation from the FDA, facilitating a pivotal single-arm study for potential approval [8] - **Commercial Opportunity**: Aiming for significant commercial potential in the AML market, with plans for a combination study later in the year [8][34] Financial Position - **Cash Reserves**: Over $430 million reported at the end of 2025, providing a runway into 2029 to advance programs without immediate capital raising needs [9] Clinical Development Updates - **Enrollment Progress**: Completed first two dose cohorts for CLN-978 and currently accruing into the 30 microgram dose level for lupus and RA studies [11] - **Efficacy Expectations**: Anticipating a dose-response effect for B cell depletion in upcoming data releases [14][15] Competitive Landscape - **Market Position**: The company aims to be the first to present company-sponsored data for a CD19 T-cell engager, enhancing competitive positioning [19] - **Strategic Acquisitions**: Acquired a BCMA TCE to expand the reach in autoimmune diseases, allowing for a broader patient base [27][28] Future Plans - **Pivotal Studies**: Plans to initiate a phase 2 single-arm study for CLN-049 in 2027, targeting relapsed refractory AML patients [40] - **Combination Studies**: Intent to begin a phase 1b/2 combination study with AZA in previously untreated AML patients [37] Zipalertinib Program - **NDA Submission**: Completion of the relapsed study marks a significant milestone, with Taiho leading further development [41] - **Financial Impact**: Potential for $130 million in regulatory milestones and a 50/50 profit share in the U.S. [42] Conclusion - **Outlook for 2026**: A defining year for Cullinan Therapeutics with multiple catalysts and significant potential in both autoimmune diseases and oncology, supported by a strong financial position and strategic development plans [9][43]